{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for exatecan in Reference Text / Citation (approximate match)
Showing 1 - 3 of 3 results
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Exatecan (DX-8951f), a new hexacyclic camptothecin analogue, is a second-generation topoisomerase
inhibitor that prevents rapidly dividing cells from
replicating by interrupting DNA transcription, ultimately
leading to cell death. Preclinical studies showed exatecan
to have broad-spectrum antitumor efficacy. Exatecan is in phase III clinical trials for the treatment of pancreas cancer. However, there is no recent report of this research. The compound was co-developed by Daiichi Pharmaceutical (now Daiichi Sankyo) and Yakult Honsha.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Exatecan (DX-8951f), a new hexacyclic camptothecin analogue, is a second-generation topoisomerase
inhibitor that prevents rapidly dividing cells from
replicating by interrupting DNA transcription, ultimately
leading to cell death. Preclinical studies showed exatecan
to have broad-spectrum antitumor efficacy. Exatecan is in phase III clinical trials for the treatment of pancreas cancer. However, there is no recent report of this research. The compound was co-developed by Daiichi Pharmaceutical (now Daiichi Sankyo) and Yakult Honsha.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Exatecan (DX-8951f), a new hexacyclic camptothecin analogue, is a second-generation topoisomerase
inhibitor that prevents rapidly dividing cells from
replicating by interrupting DNA transcription, ultimately
leading to cell death. Preclinical studies showed exatecan
to have broad-spectrum antitumor efficacy. Exatecan is in phase III clinical trials for the treatment of pancreas cancer. However, there is no recent report of this research. The compound was co-developed by Daiichi Pharmaceutical (now Daiichi Sankyo) and Yakult Honsha.